Patterns of new glucagon‐like peptide‐1 receptor agonist use in patients with type 2 diabetes during 2014–2019 from a US database: prescriber and patient characteristics

Highlights This study demonstrates that initiation of glucagon‐like peptide‐1 receptor agonists among individuals with type 2 diabetes (T2D), including those with concomitant atherosclerotic cardiovascular disease (ASCVD), has remained low in the United States between 2014 and 2019, despite clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Lingvay, Ildiko, Aroda, Vanita R., Honoré, Julie Broe, Ersbøll, Anne S., Nystrup Husemoen, Lise Lotte, Jensen, Anders Boeck, Sommer Matthiessen, Kasper, Kosiborod, Mikhail Naum
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2023
Materias:
Research Letters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9934953/
https://www.ncbi.nlm.nih.gov/pubmed/36796312
http://dx.doi.org/10.1111/1753-0407.13363

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9934953/
https://www.ncbi.nlm.nih.gov/pubmed/36796312
http://dx.doi.org/10.1111/1753-0407.13363

Ejemplares similares